Full Press Release Details
TARRYTOWN, N.Y.,Aug. 31, 2011/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) will webcast management presentations at the following investor conferences:
• Citi's 6th Annual Biotech Day panel discussion on the topic "Eye Can See Clearly Now the Rain is Gone: New Drugs for Wet AMD" at9:00 a.m. Eastern TimeonWednesday, September 7, 2011
• Morgan Stanley Global Healthcare Conference at2:45 p.m. Eastern TimeonTuesday, September 13, 2011
• UBS Global Life Sciences Conference at9:30 a.m. Eastern TimeonMonday, September 19, 2011
The sessions may be accessed through the Company's web site,www.regeneron.com, on the Investor Relations page. Archived versions of the presentations will be available for thirty days after the live webcasts.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic macular edema), and certain cancers. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site atwww.regeneron.com.
| Contact Information: | ||
| Michael Aberman, M.D. | Peter Dworkin | |
| Investor Relations | Corporate Communications | |
| 914.345.7799 | 914.345.7640 | |
| [email protected] | [email protected] | |